121 related articles for article (PubMed ID: 38320932)
1. The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
Maeda M; Murata F; Fukuda H
Vaccine; 2024 Mar; 42(7):1542-1548. PubMed ID: 38320932
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccines breakthrough infection and adverse reactions in medical students: a nationwide survey in Iran.
Allahgholipour A; Safavi-Naini SAA; Shekarriz Foomany Z; Eskandari A; Nazari Rostami H; Honarvar MJ; Mohammadi M; Khalili P; Ilaghi M; Afshar H; Amini Baghbadorani A; Moghimi HR; Chamani Goorabi A; Mehrparvar A; Safari M; Nakhli AS; Mahmoudabadi M; Seifadini A; Sheikhansari S; Khojastehfar S; Mahdavi P; Mohammadi M; Ashrafi Barzideh S; Akbarzadeh N; Delavarpour Moghadam SH; Tavakoli Pirzaman A; Barary M; Emamhadi M
Front Public Health; 2024; 12():1348015. PubMed ID: 38544731
[TBL] [Abstract][Full Text] [Related]
3. Effect of COVID-19 vaccination on household transmission of SARS-CoV-2 in the Omicron era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
Maeda M; Murata F; Fukuda H
Int J Infect Dis; 2023 Sep; 134():200-206. PubMed ID: 37356650
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization.
Stroffolini T; Ciancio A; Federico A; Benigno RG; Colloredo G; Lombardi A; Niro GA; Verucchi G; Ferrigno L; Gioli F; Marignani M
Dig Liver Dis; 2023 Mar; 55(3):316-321. PubMed ID: 36529636
[TBL] [Abstract][Full Text] [Related]
6. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
Gong IY; Vijenthira A; Powis M; Calzavara A; Patrikar A; Sutradhar R; Hicks LK; Wilton D; Singh S; Krzyzanowska MK; Cheung MC
JAMA Oncol; 2023 Mar; 9(3):386-394. PubMed ID: 36580318
[TBL] [Abstract][Full Text] [Related]
7. Objectively measured peri-vaccination sleep does not predict COVID-19 breakthrough infection.
Jaiswal SJ; Gadaleta M; Quer G; Radin JM; Waalen J; Ramos E; Pandit J; Owens RL
Sci Rep; 2024 Feb; 14(1):4655. PubMed ID: 38409137
[TBL] [Abstract][Full Text] [Related]
8. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
[TBL] [Abstract][Full Text] [Related]
9. Influenza vaccine effectiveness against hospitalization during the 2018/2019 season among older persons aged ≥ 75 years in Japan: The LIFE-VENUS Study.
Mimura W; Ishiguro C; Fukuda H
Vaccine; 2022 Aug; 40(34):5023-5029. PubMed ID: 35851488
[TBL] [Abstract][Full Text] [Related]
10. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review.
Bytyci J; Ying Y; Lee LYW
Immun Inflamm Dis; 2024 Apr; 12(4):e1259. PubMed ID: 38661301
[TBL] [Abstract][Full Text] [Related]
11. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
12. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
14. Incidence of breakthrough infections after COVID-19 vaccination among the COVID-19 vaccine recipients at a Tertiary Care Hospital in Srinagar.
Fazili A; Ain SN; Shah RJ; Raja FN; Farhat D; Nazir I
Indian J Public Health; 2023; 67(2):305-308. PubMed ID: 37459029
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
[TBL] [Abstract][Full Text] [Related]
16. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
[TBL] [Abstract][Full Text] [Related]
17. Associations between COVID-19 vaccination and incident psychiatric disorders after breakthrough SARS-CoV-2 infection: The VENUS Study.
Murata F; Maeda M; Murayama K; Nakao T; Fukuda H
Brain Behav Immun; 2024 Mar; 117():521-528. PubMed ID: 38355026
[TBL] [Abstract][Full Text] [Related]
18. Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
Fukuda H; Maeda M; Murata F
Vaccine; 2023 May; 41(23):3556-3563. PubMed ID: 37037707
[TBL] [Abstract][Full Text] [Related]
19. Results of the Cologne Corona Surveillance (CoCoS) project- a cross-sectional study: survey data on risk factors of SARS-CoV-2 infection, and moderate-to-severe course in primarily immunized adults.
Oberste M; Asenova T; Ernst A; Shah-Hosseini K; Schnörch N; Buess M; Rosenberger KD; Kossow A; Dewald F; Neuhann F; Hellmich M
BMC Public Health; 2024 Feb; 24(1):548. PubMed ID: 38383381
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
